These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice. Sii-Felice K; Giorgi M; Leboulch P; Payen E Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062 [TBL] [Abstract][Full Text] [Related]
4. Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease. Kanter J; Walters MC; Krishnamurti L; Mapara MY; Kwiatkowski JL; Rifkin-Zenenberg S; Aygun B; Kasow KA; Pierciey FJ; Bonner M; Miller A; Zhang X; Lynch J; Kim D; Ribeil JA; Asmal M; Goyal S; Thompson AA; Tisdale JF N Engl J Med; 2022 Feb; 386(7):617-628. PubMed ID: 34898139 [TBL] [Abstract][Full Text] [Related]
5. Restoration of β-Globin Expression with Optimally Designed Lentiviral Vector for β-Thalassemia Treatment in Chinese Patients. Ouyang W; Dong G; Zhao W; Li J; Zhou Z; Yang G; Liu R; Li Y; Zhang Q; Du X; Sun H; Gu Y; Lai Y; Liu S; Liu C Hum Gene Ther; 2021 May; 32(9-10):481-494. PubMed ID: 33256481 [TBL] [Abstract][Full Text] [Related]
6. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial. Boulad F; Maggio A; Wang X; Moi P; Acuto S; Kogel F; Takpradit C; Prockop S; Mansilla-Soto J; Cabriolu A; Odak A; Qu J; Thummar K; Du F; Shen L; Raso S; Barone R; Di Maggio R; Pitrolo L; Giambona A; Mingoia M; Everett JK; Hokama P; Roche AM; Cantu VA; Adhikari H; Reddy S; Bouhassira E; Mohandas N; Bushman FD; Rivière I; Sadelain M Nat Med; 2022 Jan; 28(1):63-70. PubMed ID: 34980909 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial. Magrin E; Semeraro M; Hebert N; Joseph L; Magnani A; Chalumeau A; Gabrion A; Roudaut C; Marouene J; Lefrere F; Diana JS; Denis A; Neven B; Funck-Brentano I; Negre O; Renolleau S; Brousse V; Kiger L; Touzot F; Poirot C; Bourget P; El Nemer W; Blanche S; Tréluyer JM; Asmal M; Walls C; Beuzard Y; Schmidt M; Hacein-Bey-Abina S; Asnafi V; Guichard I; Poirée M; Monpoux F; Touraine P; Brouzes C; de Montalembert M; Payen E; Six E; Ribeil JA; Miccio A; Bartolucci P; Leboulch P; Cavazzana M Nat Med; 2022 Jan; 28(1):81-88. PubMed ID: 35075288 [TBL] [Abstract][Full Text] [Related]
8. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. Locatelli F; Lang P; Wall D; Meisel R; Corbacioglu S; Li AM; de la Fuente J; Shah AJ; Carpenter B; Kwiatkowski JL; Mapara M; Liem RI; Cappellini MD; Algeri M; Kattamis A; Sheth S; Grupp S; Handgretinger R; Kohli P; Shi D; Ross L; Bobruff Y; Simard C; Zhang L; Morrow PK; Hobbs WE; Frangoul H; N Engl J Med; 2024 May; 390(18):1663-1676. PubMed ID: 38657265 [TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease. Negre O; Bartholomae C; Beuzard Y; Cavazzana M; Christiansen L; Courne C; Deichmann A; Denaro M; de Dreuzy E; Finer M; Fronza R; Gillet-Legrand B; Joubert C; Kutner R; Leboulch P; Maouche L; Paulard A; Pierciey FJ; Rothe M; Ryu B; Schmidt M; von Kalle C; Payen E; Veres G Curr Gene Ther; 2015; 15(1):64-81. PubMed ID: 25429463 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients. Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321 [TBL] [Abstract][Full Text] [Related]
11. Wild-type HIV infection after treatment with lentiviral gene therapy for β-thalassemia. Hongeng S; Anurathapan U; Songdej D; Phuphuakrat A; Jongrak K; Parsons G; Deary B; Bonner M; Veres G; Asmal M Blood Adv; 2021 Jul; 5(13):2701-2706. PubMed ID: 34196676 [TBL] [Abstract][Full Text] [Related]
12. Hemoglobin gene therapy for β-thalassemia. Bank A Hematol Oncol Clin North Am; 2010 Dec; 24(6):1187-201. PubMed ID: 21075288 [TBL] [Abstract][Full Text] [Related]
13. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Bank A; Dorazio R; Leboulch P Ann N Y Acad Sci; 2005; 1054():308-16. PubMed ID: 16339679 [TBL] [Abstract][Full Text] [Related]
14. Coordinated β-globin expression and α2-globin reduction in a multiplex lentiviral gene therapy vector for β-thalassemia. Nualkaew T; Sii-Felice K; Giorgi M; McColl B; Gouzil J; Glaser A; Voon HPJ; Tee HY; Grigoriadis G; Svasti S; Fucharoen S; Hongeng S; Leboulch P; Payen E; Vadolas J Mol Ther; 2021 Sep; 29(9):2841-2853. PubMed ID: 33940155 [TBL] [Abstract][Full Text] [Related]
15. Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study. Kanter J; Thompson AA; Pierciey FJ; Hsieh M; Uchida N; Leboulch P; Schmidt M; Bonner M; Guo R; Miller A; Ribeil JA; Davidson D; Asmal M; Walters MC; Tisdale JF Am J Hematol; 2023 Jan; 98(1):11-22. PubMed ID: 36161320 [TBL] [Abstract][Full Text] [Related]
19. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders. Persons DA Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255 [TBL] [Abstract][Full Text] [Related]
20. Gene addition for beta thalassemia. Kwiatkowski JL Ann N Y Acad Sci; 2023 Dec; 1530(1):105-109. PubMed ID: 37828865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]